文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

基因组学与功能影像预测舒尼替尼药代与药效的探索性研究

The utility of genomics and functional imaging to predict sunitinib pharmacokinetics and pharmacodynamics: The predict SU study.
PubMed 文献 · Br J Clin Pharmacol · 2026-01-04

本研究纳入15例适合舒尼替尼治疗的患者,采用DMET芯片和Sanger测序进行药物基因组学检测,并用99mTc-MIBI肝动态显像评估肝功能参数,探索其与舒尼替尼药代动力学、毒性/疗效及无进展生存期的关联。结果发现多个基因变异和肝显像参数与舒尼替尼及其代谢物的AUC、腹泻、≥3级不良事件、客观缓解率和PFS存在探索性关联,但需进一步验证。

要点

  • 肝显像参数HEF与舒尼替尼及其代谢物早期AUC相关,或可辅助预测暴露水平。
  • ATP7B、UGT8、SLC15A1、SLC10A2等基因变异与舒尼替尼或代谢物AUC存在关联。
  • VEGFR3、AKAP9、CBR1等基因变异与腹泻或≥3级不良事件相关,但证据尚待验证。

核心结论

  • 舒尼替尼药代动力学和药效学与肝功能显像参数及广泛药物基因组学变异存在探索性关联,需进一步验证。

研究设计与样本

  • 单中心探索性研究,纳入15例适合舒尼替尼治疗的患者。
  • 基线进行DMET Plus芯片(1936个变异/225个基因)和Sanger测序检测HNF1A、FLT3、VEGFR2、VEGFR3、RET、PDGFRα、TNFα。
  • 基线行99mTc-MIBI肝动态显像获取CLHNI、T1/2-HNI、1hRET、HEF、Td1/2等参数。
  • 第1和2周期采血检测舒尼替尼原药、代谢物SU12662及总舒尼替尼药代动力学。

临床怎么用

  • 目前证据尚不足以指导临床常规剂量调整或患者选择,相关基因和影像标志物仅用于研究背景下的探索。

局限性

  • 样本量仅15例,关联分析为探索性,未进行多重比较校正。
  • 结果需在更大样本中独立验证后才能用于临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Sunitinib has marked pharmacokinetic (PK) and pharmacodynamic (PD) interpatient variability. This study evaluated the utility of extensive excretory/metabolic/PD pharmacogenomics (PGx) with hepatic functional imaging (HNI) to explore their associations with sunitinib PK/PD (toxicity/response) and progression-free survival (PFS), respectively. METHODS: Eligible patients (pts) suitable for sunitinib therapy. At baseline: (i) PGx: blood analysed by the Affymetrix DMET™ Plus Array (1936 variants/225 genes) and Sanger sequencing (HNF1A, FLT3, VEGFR2, VEGFR3, RET, PDGFRα, TNFα). (ii) HNI: pts given IV 800 MBq 99mTc-MIBI, imaging data analysed for hepatic extraction/excretion parameters (CLHNI, T1/2-HNI, 1hRET, HEF, Td1/2). In cycles 1 and 2, bloods taken for sunitinib parent (SU), metabolite (SU12662) and total SU (metabolite + parent) PK. Associations evaluated between (i) HNI parameters and (2) PGx, with sunitinib PK, toxicity/response and PFS. RESULTS: N = 15 pts. The two most significant associations in either direction between PGx variants or HNI parameters (p < .05) for: (i) PK included: (a) SU logAUC0-14days with HEF, ATP7B (rs1801246) and UGT8 (rs4148254); (b) SU logAUC0-28days, with Td1/2, SLC15A1 (rs8187832) and SLC10A2 (rs188096); (c) SU12662 logAUC0-14days with HEF, ABCC3 (rs11568591), PPARD (rs1003973) and SLC15A1 (rs8187840); and (d) SU12662 logAUC0-28days with SULT1A2 (rs1059491) and SLC10A2 (rs188096). (ii) Toxicity: (a) Diarrhoea grade 1+ with HEF, VEFGR3 (rs307826) and AKAP9 (rs7785971); (b) ≥grade 3 AEs with CBR1 (rs998383); (iii) overall response rate with SULT1E1 (rs1881668) and GSTA2 (rs2180314); and (iv) PFS with CYP4Z1 (rs4926802) and CYP2A6 (rs28399442). CONCLUSIONS: Exploratory associations were observed between sunitinib PK/PD with hepatic functional imaging with extensive pharmacogenomics. Further validation is required.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Michael M, Toner GC, Ganju V, et al. The utility of genomics and functional imaging to predict sunitinib pharmacokinetics and pharmacodynamics: The predict SU study. Br J Clin Pharmacol. 2026. PMID: 41485482. doi:10.1002/bcp.70431

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。